Welcome to our dedicated page for Nautilus Biotechnology SEC filings (Ticker: NAUT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Nautilus Biotechnology, Inc. (NAUT) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed development stage life sciences company building a single-molecule proteome analysis platform, Nautilus uses filings such as Forms 10-K, 10-Q, and 8-K to report financial results, operational updates, and other material events related to its business.
Investors reviewing NAUT filings can examine periodic reports for details on research and development and general and administrative expenses, net losses, and cash, cash equivalents, and investments, which reflect the company’s development stage profile. These filings also describe risk factors associated with Nautilus’ efforts to develop and validate its proteome analysis platform, including the scientific and technical challenges of bringing a highly novel product to market and uncertainties around timelines for validation and commercialization.
Current reports on Form 8-K are particularly relevant for tracking significant events at Nautilus. For example, the company has filed 8-Ks to furnish quarterly earnings press releases and to disclose matters such as the outcome of its annual meeting of stockholders and changes in Nasdaq listing status. One Form 8-K describes a notice from Nasdaq indicating that Nautilus had not met the minimum bid price requirement for continued listing on the Nasdaq Global Select Market and the subsequent transfer to The Nasdaq Capital Market. A later Form 8-K reports that Nautilus regained compliance with Nasdaq’s minimum bid price rule after its closing bid price met or exceeded $1.00 per share for at least ten consecutive business days.
Through this page, users can also monitor governance-related disclosures, including information about director elections and auditor ratification reported under Item 5.07 of Form 8-K. In addition, Nautilus’ filings reference its status as an emerging growth company and its use of SEC filings, press releases, webcasts, and its website as channels for disclosing material information. Stock Titan’s interface surfaces these filings with AI-powered summaries that help explain the context and key points, allowing readers to quickly understand the implications of lengthy documents such as annual reports, quarterly reports, and current reports on Form 8-K without reading every line.
Nautilus Biotechnology, Inc. is holding its 2026 annual stockholder meeting virtually on June 17, 2026 at 10:00 a.m. Pacific Time. Holders of common stock as of April 20, 2026, when 127,078,855 shares were outstanding, may attend and vote online using a 16‑digit control number.
Stockholders will vote on electing two Class II directors through 2029, ratifying PricewaterhouseCoopers LLP as auditor for 2026, approving 2025 executive compensation on an advisory basis, and choosing how often to hold future say‑on‑pay votes. The board recommends voting for all proposals and selecting “one year” for say‑on‑pay frequency.
Nautilus Biotechnology reported a Q1 2026 net loss of $14.7 million, an improvement from $16.6 million a year earlier, as it continues developing its Nautilus Voyager proteomics platform with no product revenue yet. Research and development expenses fell to $9.7 million and selling, general and administrative costs declined to $6.4 million, reflecting prior cost reductions.
The company held $95.9 million in cash, cash equivalents and short‑term investments and $143.4 million including long‑term investments as of March 31, 2026, and believes this will fund operations for at least the next twelve months while it advances its Early Access Program and phased commercial launch planned for 2026–2027.
Nautilus Biotechnology reported first quarter 2026 results, showing lower spending and a narrower loss as it advances its proteomics platform toward commercialization. Operating expenses were $16.1 million, down 14% from $18.8 million a year earlier, mainly from lower salaries, stock-based compensation, and facilities costs.
Net loss improved to $14.7 million for the quarter, compared with $16.6 million in the prior-year period, or $0.12 per share versus $0.13. Cash, cash equivalents, and investments totaled $143.4 million as of March 31, 2026, supporting ongoing development of the Voyager platform and the new Iterative Mapping Early Access Program.
During the quarter, Nautilus initiated its Iterative Mapping Early Access Program with Baylor College of Medicine, advanced Tau proteoform assay work with collaborators, and appointed a new Vice President of Global Sales to drive early customer expansion ahead of full commercial launch.
Nautilus Biotechnology insider Sujal Patel now reports beneficial ownership of 21,249,965 shares of common stock, representing 16.3% of the company. This total includes shares he holds directly, through an LLC, through a children’s trust, and through stock options.
The filing explains that 10,366,721 shares are directly owned by Patel, 5,280,476 shares are held by PFV I, LLC, and 1,814,035 shares are held by the Sujal Patel 2020 Children's Trust, over which he and his spouse share voting and dispositive power. A further 3,788,733 shares are issuable upon exercise of options.
As of March 2, 2026, 2,326,231 of these option shares are exercisable within 60 days. On March 2, 2026 Patel received an option grant for 650,000 shares, and on March 4, 2026 he bought 25,000 shares of Nautilus Biotechnology common stock on the open market.
Parag Mallick filed Amendment No. 2 to update his beneficial ownership of Nautilus Biotechnology common stock. He reports beneficial ownership of 22,557,411 shares, representing 17.6% of the company’s common stock, based on 126,564,473 shares outstanding plus his option shares.
The total includes 20,493,392 shares held directly, options to purchase 1,864,019 shares, and 200,000 shares held by The Dream Finder Foundation over which he and his spouse share voting and dispositive power. On March 2, 2026, he was granted an additional option to buy 280,000 shares, with vesting subject to continued service and full acceleration upon certain change-in-control termination events.
Nautilus Biotechnology, Inc. director and CEO Sujal M. Patel reported an open-market purchase of 25,000 shares of Common Stock at a weighted average price of $2.6095 per share. Following this buy, he directly owns 10,366,721 common shares.
He also reports indirect ownership of 5,280,476 common shares held by PFV I, LLC, for which he is the manager, and 1,814,035 common shares held by the Sujal Patel 2020 Children's Trust, where he and his spouse serve as trustees.
Nautilus Biotechnology reported that its CFO and Treasurer, Anna Mowry, received a grant of stock options covering 160,000 shares of common stock. The options were awarded at an exercise price of $0.00 per share, reflecting a compensatory grant rather than an open-market purchase.
According to the award’s vesting terms, 25% of the options will vest on the one-year anniversary of the vesting commencement date of January 1, 2026, with the remaining shares vesting in equal monthly installments over the following 36 months, contingent on her continued service as a “Service Provider.”
Mallick Parag reported acquisition or exercise transactions in this Form 4 filing.
Nautilus Biotechnology, Inc. reported that Chief Scientist and 10% owner Parag Mallick was granted stock options covering 280,000 shares of common stock. These options were awarded on March 2, 2026 and are structured as a long-term equity incentive.
The grant vests over time, subject to Mallick’s continued service to the company. Twenty-five percent of the options vest on the one-year anniversary of the January 1, 2026 vesting commencement date, with the remaining options vesting in equal monthly installments over the following thirty-six months.
Nautilus Biotechnology CEO Sujal M. Patel received a grant of 650,000 stock options described as a right to buy shares at an exercise price of $0.0000 per share. According to the vesting terms, 25% of the options vest on the one-year anniversary of the vesting commencement date of January 1, 2026, with the remaining shares vesting in equal monthly installments over the following 36 months, contingent on his continued service.